PROTEOMICS Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PROTEOMICS

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (529)	4/1/2005 8:26:48 AM
From: nigel bates	Read Replies (1) of 539

tuck, how much credence do you give this ? Message 21188702 Proteome Sciences plc ('Proteome Sciences' or the 'Company') is pleased to announce that it has signed Heads of Agreement for an exclusive global license in the field of proteomics with a major global healthcare player for its Tandem Mass Tags, part of the Sensitizer family of chemical reagents and expects to complete the definitive licence agreement shortly, at which time full details of the licensee will be disclosed... The Board believes that the market potential for isobaric mass tag reagents in proteomics is likely to grow extremely rapidly and is projected to generate sales into many hundreds of million dollars over the TMT patent life... (There's also an interesting mention of RNA therapy in there...) Not followed them for a while, but looks interesting. (Current market cap. somewhat under $200m).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next